Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...

March Biosciences, a startup spun out of Baylor College of Medicine's Center for Cell and Gene Therapy, landed a Series A ...

MU Health Care said the new program is the only one of its kind in the region, and may help patients get care without going ...

In 1893, the American Journal of the Medical Sciences reported on 10 patients whose large and hitherto incurable cancers had ...

Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at ...

This study, being conducted in South Africa, is similar to ImmunityBio’s U.S.-based trial QUILT 3.092, a phase 1 open-label study of CD19 t-haNK as a single agent and in combination with the company’s ...

With this fundamental mechanism worked out, the team explored an immunotherapy called chimeric antigen receptor T (CAR T) ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received an average rating of “Moderate Buy” from the nine ...